Skip to content

The effectiveness of transcranial direct current stimulation in the treatment of auditory neuropathy: A clinical trial

The effectiveness of transcranial direct current stimulation in the treatment of auditory neuropathy: A clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081051
Enrollment
Unknown
Registered
2024-02-21
Start date
2024-03-01
Completion date
Unknown
Last updated
2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Auditory Neuropathy

Interventions

Experimental group :Anodal stimulation of transcranial direct current stimulation
Control group :Sham stimulation of transcranial direct current stimulation

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria for subjects in the AN group were as follows: 1) Age 18~40 years old, head circumference 55~60cm, and healthy except for hearing problems; 2) Confirmed diagnosis of AN: severe abnormalities of auditory brainstem response; otoacoustic emissions can be elicited and contralateral suppression test fails; normal acoustic conductance tympanogram, loss of stapedial muscle reflex or elevated threshold; abnormal cochlea electrogram-SP/AP ratio; normal pure tone audiometry or mild to severe hearing loss; disproportionate decrease in speech recognition rate and pure tone hearing and the speech recognition rate is >12%. 3) Subjects or those who have signed an informed consent form by an authorized relative of the subject. The inclusion criteria for normal hearing subjects were as follows: 1) Age and gender matched to the AN group, with a head circumference of 55-60 cm; 2) Normal hearing and good health.

Exclusion criteria

Exclusion criteria: Exclusion criteria for subjects in the AN group were as follows: 1) Exclusion of cognitive dysfunction; 2) Comorbid severe neurological disorders; 3) Diagnosis of syndromic type diseases; 4) Implantation of metal and electronic devices in the body; 5) Participation in other clinical trials within 3 months; 6) Those with bleeding tendency or coagulation disorder; 7) Those who are not suitable to wear the test instruments in the stimulated area.

Design outcomes

Primary

MeasureTime frame
Speech recognition score;

Secondary

MeasureTime frame
MoCA Scale Score;

Countries

China

Contacts

Public ContactQiuju Wang

Chinese PLA General Hospital

wqcr301@vip.sina.com+86 10 5549 9143

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026